BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

563 related articles for article (PubMed ID: 14983224)

  • 1. Turbulent axially directed flow of plasma containing rt-PA promotes thrombolysis of non-occlusive whole blood clots in vitro.
    Tratar G; Blinc A; Strukelj M; Mikac U; Sersa I
    Thromb Haemost; 2004 Mar; 91(3):487-96. PubMed ID: 14983224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Flow through clots determines the rate and pattern of fibrinolysis.
    Blinc A; Kennedy SD; Bryant RG; Marder VJ; Francis CW
    Thromb Haemost; 1994 Feb; 71(2):230-5. PubMed ID: 8191404
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A mathematical model for the dissolution of non-occlusive blood clots in fast tangential blood flow.
    Sersa I; Tratar G; Mikac U; Blinc A
    Biorheology; 2007; 44(1):1-16. PubMed ID: 17502685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of retraction on the lysis of human clots with fibrin specific and non-fibrin specific plasminogen activators.
    Sabovic M; Lijnen HR; Keber D; Collen D
    Thromb Haemost; 1989 Dec; 62(4):1083-7. PubMed ID: 2515603
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Whole blood clot lysis in newborns and adults after adding different concentrations of recombinant tissue plasminogen activator (Rt-PA).
    Trusen B; Ries M; Zenker M; Rauh M; Beinder E; Keuper H; Harms D
    Semin Thromb Hemost; 1998; 24(6):599-604. PubMed ID: 10066156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modelling the effect of laminar axially directed blood flow on the dissolution of non-occlusive blood clots.
    Sersa I; Vidmar J; Grobelnik B; Mikac U; Tratar G; Blinc A
    Phys Med Biol; 2007 Jun; 52(11):2969-85. PubMed ID: 17505083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro clot lysis as a potential indicator of thrombus resistance to fibrinolysis--study in healthy subjects and correlation with blood fibrinolytic parameters.
    Colucci M; Scopece S; Gelato AV; Dimonte D; Semeraro N
    Thromb Haemost; 1997 Apr; 77(4):725-9. PubMed ID: 9134650
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biochemical and biophysical conditions for blood clot lysis.
    Sabovic M; Blinc A
    Pflugers Arch; 2000; 440(5 Suppl):R134-6. PubMed ID: 11005642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of flow on lysis of plasma clots in a plasma environment.
    Sakharov DV; Rijken DC
    Thromb Haemost; 2000 Mar; 83(3):469-74. PubMed ID: 10744155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dependence of blood clot lysis on the mode of transport of urokinase into the clot--a magnetic resonance imaging study in vitro.
    Blinc A; Planinsic G; Keber D; Jarh O; Lahajnar G; Zidansĕk A; Demsar F
    Thromb Haemost; 1991 May; 65(5):549-52. PubMed ID: 1871717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lysing patterns of retracted blood clots with diffusion or bulk flow transport of plasma with urokinase into clots--a magnetic resonance imaging study in vitro.
    Blinc A; Keber D; Lahajnar G; Stegnar M; Zidansek A; Demsar F
    Thromb Haemost; 1992 Dec; 68(6):667-71. PubMed ID: 1287880
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Direct microscopic monitoring of initial and dynamic clot lysis using plasmin or rt-PA in an in vitro flow system.
    Bizjak N; Bajd F; Vidmar J; Blinc A; Perme MP; Marder VJ; Novokhatny V; Serša I
    Thromb Res; 2014 May; 133(5):908-13. PubMed ID: 24613694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sonothrombolysis is effective with recombinant tissue-type plasminogen activator, but not with Abciximab. Results from an in vitro study with whole blood clots and platelet-rich clots.
    Eggers J; Ossadnik S; Hütten H; Seidel G
    Thromb Haemost; 2009 Dec; 102(6):1274-7. PubMed ID: 19967161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Properties of thrombolytic agents in vitro using a perfusion circuit attaining shear stress at physiological levels.
    Nishino N; Scully MF; Rampling MW; Kakkar VV
    Thromb Haemost; 1990 Dec; 64(4):550-5. PubMed ID: 2128138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Depletion of plasminogen in vitro or during thrombolytic therapy limits fibrinolytic potential.
    Onundarson PT; Francis CW; Marder VJ
    J Lab Clin Med; 1992 Jul; 120(1):120-8. PubMed ID: 1613318
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vampire bat salivary plasminogen activator promotes robust lysis of plasma clots in a plasma milieu without causing fluid phase plasminogen activation.
    Hare TR; Gardell SJ
    Thromb Haemost; 1992 Aug; 68(2):165-9. PubMed ID: 1412162
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Local thrombolysis in peripheral arterial occlusion].
    Hess H
    Herz; 1989 Feb; 14(1):12-21. PubMed ID: 2522076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of concomitant thrombin-mediated fibrin formation enhances clot lysis in whole blood.
    Haskel EJ; Eisenberg PR; Abendschein DR
    Blood Coagul Fibrinolysis; 1993 Feb; 4(1):7-13. PubMed ID: 8457655
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Streptokinase and rt-PA activate platelets by a different way: implications on the rethrombosis rate after their administration in myocardial infarction.
    Parise P; Hauert J; Iorio A; Callegari P; Agnelli G
    J Lab Clin Med; 1995 Feb; 125(2):212-21. PubMed ID: 7531212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of local thrombolytic efficacy of plasmin and rt-PA in an in-vitro flow system; a pilot study.
    Bizjak N; Bajd F; Vidmar J; Blinc A; Marder VJ; Novokhatny V; Serša I
    Blood Coagul Fibrinolysis; 2013 Oct; 24(7):711-4. PubMed ID: 23751605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.